Down-regulation and deficient expression of PPARα are associated with the development of NASH, and treatment with agonist for PPARα prevents and inhibits the development of NAFLD[21,22]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.